» Articles » PMID: 11158220

Identification of Receptor Ligands by Screening Phage-display Peptide Libraries Ex Vivo on Microdissected Kidney Tubules

Overview
Specialty Nephrology
Date 2001 Feb 7
PMID 11158220
Citations 11
Authors
Affiliations
Soon will be listed here.
Abstract

A novel method to identify receptor ligands for defined renal tubular segments has been developed. Ex vivo screening of phage-display peptide libraries on isolated intact rat proximal convoluted tubules (PCT) and cortical collecting ducts (CCD) allowed the direct access of phage to the basolateral surface of tubular epithelial cells. Two distinct peptide motifs were selected for CCD and PCT, indicating differential expression of some membrane receptors on the basolateral surface of defined kidney tubule segments. Using the linear peptide motif ELRGD(R/M)AX(W/L), recovered from freshly isolated rat CCD, mediated 16-fold selectivity of phage binding to CCD compared with PCT. Binding to CCD was 39-fold higher than that of a random control phage. Binding and subsequent internalization of phage, most likely by an integrin-mediated endocytosis pathway, was abolished by the addition of the corresponding synthetic peptide. Furthermore, the results demonstrate that presentation and flanking amino acids determine the specific binding properties of RGD ligands to their putative integrin receptors. The results emphasize the need of a native cell system for the identification of renal epithelial cell surface ligands. Such ligands are of potential relevance for the analysis of interactions between extracellular matrix and kidney tubules or for the development of improved vectors for kidney-specific drug delivery or gene transfer.

Citing Articles

Phage Display Technology in Biomarker Identification with Emphasis on Non-Cancerous Diseases.

Sadraeian M, Maleki R, Moraghebi M, Bahrami A Molecules. 2024; 29(13).

PMID: 38998954 PMC: 11243120. DOI: 10.3390/molecules29133002.


Spotlight on Genetic Kidney Diseases: A Call for Drug Delivery and Nanomedicine Solutions.

Trac N, Ashraf A, Giblin J, Prakash S, Mitragotri S, Chung E ACS Nano. 2023; 17(7):6165-6177.

PMID: 36988207 PMC: 10145694. DOI: 10.1021/acsnano.2c12140.


A Urinary Drug-Disposing Approach as an Alternative to Intravesical Chemotherapy for Treating Nonmuscle Invasive Bladder Cancer.

Bellat V, Michel A, Thomas C, Stokol T, Choi B, Law B Cancer Res. 2022; 82(7):1409-1422.

PMID: 35039320 PMC: 8983499. DOI: 10.1158/0008-5472.CAN-21-2897.


Improving kidney targeting: The influence of nanoparticle physicochemical properties on kidney interactions.

Huang Y, Wang J, Jiang K, Chung E J Control Release. 2021; 334:127-137.

PMID: 33892054 PMC: 8192458. DOI: 10.1016/j.jconrel.2021.04.016.


Targeting and therapeutic peptide-based strategies for polycystic kidney disease.

Wang J, Tripathy N, Chung E Adv Drug Deliv Rev. 2020; 161-162:176-189.

PMID: 32866560 PMC: 7736157. DOI: 10.1016/j.addr.2020.08.011.